`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_______________________
`
`AQUESTIVE THERAPEUTICS, INC.
`
`
`Petitioner
`
`v.
`
`NEURELIS, INC.
`
`Patent Owner
`
`_______________________
`
`Case: IPR2019-00451
`
`U.S. Patent No. 9,763,876
`
`______________________
`
`
`
`PETITIONER’S OBJECTIONS
`
`PURSUANT TO 37 C.F.R. § 42.64(b)(1)
`
`SECOND SET
`
`
`
`
`IPR2019-00451
`
`
`
`
`
`U.S. Patent No. 9,763,876
`
`TABLE OF CONTENTS
`
`OBJECTIONS ............................................................................................................ 1
`Exhibit 2028: “Intranasal Technology, Inc. Licenses Aegis Therapeutics'
`
`Intravail Drug Delivery Technology” (Business Wire) (April 13, 2005).............. 1
`
`FRE 402 (relevance); FRE 403 (confusion, waste, prejudice) .......................... 1
`
`FRE 802 (hearsay without exception) ............................................................... 1
`
`FRE 901 (authentication) ................................................................................... 1
`
`FRE 105 (limited purpose) ................................................................................. 1
`
`Exhibit 2030: J. Wyse, U.S. Patent No. 9,192,570 issued November 24, 2015 . 2
`
`FRE 402 (relevance); FRE 403 (confusion, waste, prejudice) .......................... 2
`
`FRE 105 (limited purpose) ................................................................................. 2
`
`
`
`
`
`
`
`i
`
`
`
`
`
`
`IPR2019-00451
`
`
`
`
`
`U.S. Patent No. 9,763,876
`
`OBJECTIONS
`
`
`
`Petitioner, Aquestive Therapeutics, Inc. submits the following objections to
`
`evidence of the Patent Owner, Neurelis, Inc.
`
`Exhibit 2028: “Intranasal Technology, Inc. Licenses Aegis Therapeutics'
`Intravail Drug Delivery Technology” (Business Wire) (April
`13, 2005)
`
`
`
`
`FRE 402 (relevance); FRE 403 (confusion, waste, prejudice)
`
`The exhibit is not cited in Patent Owner’s Sur-Reply (Paper 28) and is not relevant
`
`to any instituted ground. The exhibit’s probative value is substantially outweighed
`
`by its confusion of the issues to be decided, its waste of the Board’s and the
`
`Petitioner’s time, and the danger that it will lead to unfair prejudice if used later in
`
`the proceeding or on appeal.
`
`
`
`FRE 802 (hearsay without exception)
`
`The exhibit is offered to prove the truth of the matter asserted without
`
`meeting any hearsay exception.
`
`
`
`FRE 901 (authentication)
`
`Patent Owner failed to provide evidence sufficient to establish the exhibit is
`
`what it is purported to be.
`
`
`
`FRE 105 (limited purpose)
`
`If the exhibit is admitted, its use should be limited to the purpose for which
`
`1
`
`
`
`
`
`
`IPR2019-00451
`
`
`it was offered in Patent Owner’s Sur-Reply (Paper 28).
`
`
`
`U.S. Patent No. 9,763,876
`
`Exhibit 2030: J. Wyse, U.S. Patent No. 9,192,570 issued November 24, 2015
`
`
`
`FRE 402 (relevance); FRE 403 (confusion, waste, prejudice)
`
`The exhibit is not relevant to any instituted ground. The exhibit’s probative value
`
`is substantially outweighed by its confusion of the issues to be decided, its waste of
`
`the Board’s and the Petitioner’s time, and the danger that it will lead to unfair
`
`prejudice if used later in the proceeding or on appeal.
`
`
`
`FRE 105 (limited purpose)
`
`If the exhibit is admitted, its use should be limited to the purpose for which
`
`it was offered in Patent Owner’s Sur-Reply (Paper 28).
`
`
`
`
`
`Dated: March 17, 2019.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Michael I. Chakansky/
`Michael I. Chakansky (Reg. No. 31,600)
`Hoffmann & Baron, LLP
`4 Century Drive
`
`Parsippany, N.J. 07054
`mchakansky@hbiplaw.com
`Tel: 973.331.1700
`
`
`
`First Backup Counsel for
`Petitioner Aquestive Therapeutics, Inc.
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`
`
`
`
`
`IPR2019-00451
`
`
`
`
`
`U.S. Patent No. 9,763,876
`
`CERTIFICATE OF SERVICE
`
`
`
`I hereby certify that on this the 17th day of March 2020, the foregoing
`
`PETITIONER’S OBJECTIONS PURSUANT TO 37 C.F.R. § 42.64(b)(1)
`
`SECOND SET was served in its entirety on the following counsel of record by
`
`electronic service by email at the email addresses as set forth below.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Jeffrey Guise
`Richard Torczon
`Lorelei Westin
`Lee Johnson
`Nathaniel Leachman
`Alina L. Litoshyk
`Wendy Devine
`WILSON SONSINI GOODRICH & ROSATI
`jguise@wsgr.com
`rtorczon@wsgr.com
`lwestin@wsgr.com
`ljohnson@wsgr.com
`nleachman@wsgr.com
`alitoshyk@wsgr.com
`wdevine@wsgr.com
`35401.652.palib1@matters.wsgr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By:
`
`
`
`
`
`
`
`/Michael I. Chakansky/
`Michael I. Chakansky (Reg. No. 31,600)
`Hoffmann & Baron, LLP
`4 Century Drive
`
`Parsippany, N.J. 07054
`mchakansky@hbiplaw.com
`Tel: 973.331.1700
`
`
`
`3
`
`